Tokyo - The U.S. District Court for the Eastern District of Texas issued an amended final judgment on October 17, 2023 (Central Time) in a patent litigation filed by Seagen Inc. against Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo).

The District Court's amended final judgment requires Daiichi Sankyo to pay Seagen a royalty of 8% on sales of ENHERTU from April 1, 2022 through November 4, 2024 (the expiry of U.S. Patent 10,808,039) in addition to the $41.8 million in damages previously awarded by the Court following the jury's verdict. The District Court entered the amended final judgment after its denial of Daiichi Sankyo's motions for judgment as a matter of law, or alternatively, a new trial, and its resolution of motions seeking clarification of prior orders. Daiichi Sankyo had made those motions in response to the April 8, 2022 jury verdict. The District Court also denied Seagen's request for attorneys' fees. Daiichi Sankyo intends to appeal the amended final judgment.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need.

Contact:

Tel: +81-3-6225-1126

Web: https://www.daiichisankyo.com

(C) 2023 Electronic News Publishing, source ENP Newswire